FDA approves first vaccine for RSV, a moment six decades in the ... - CNN
WEBMay 3, 2023 · On Wednesday, the US Food and Drug Administration approved Arexvy, made by GSK, which is designed to be given as a single shot to adults 60 and older. Late-stage RSV vaccine trials show 'exciting...
FDA Approves First Respiratory Syncytial Virus (RSV) Vaccine
WEBMay 4, 2023 · Today, the U.S. Food and Drug Administration approved Arexvy, the first respiratory syncytial virus (RSV) vaccine approved for use in the United States. Arexvy is approved for the...
US FDA approves GSK’s AREXVY, the world’s first respiratory …
WEBMay 3, 2023 · US FDA approves GSK’s AREXVY, the world’s first respiratory syncytial virus (RSV) vaccine for older adults. Ground-breaking approval enables adults aged 60 years and older to be protected from RSV disease for the first time.
US FDA approves expanded age indication for GSK’s AREXVY, the …
WEBJun 7, 2024 · GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved AREXVY (Respiratory Syncytial Virus (RSV) Vaccine, Adjuvanted) for the prevention of RSV lower respiratory tract disease (LRTD) in adults 50 through 59 years of age who are at increased risk.
GSK Announces Positive Topline Data on Co-Administration of AREXVY …
WEB2 days ago · About AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) AREXVY contains recombinant RSV glycoprotein F stabilized in the prefusion conformation (RSVPreF3). This antigen is combined with GSK’s proprietary AS01E adjuvant. The vaccine has been approved for the prevention of RSV-LRTD in individuals 60 years of age and older in 50 countries ...
Federal Officials Revise Recommendations for R.S.V. Vaccine
WEBJun 26, 2024 · The Food and Drug Administration has approved three R.S.V. vaccines. Two of them, GSK’s Arexvy and Pfizer’s Abrysvo, were approved in May last year and were administered during the fall and...
New data for AREXVY, GSK’s RSV vaccine, show potential to help …
WEBOct 25, 2023 · New data for AREXVY, GSK’s RSV vaccine, show potential to help protect adults aged 50 to 59 at increased risk for RSV disease. Preliminary results from phase III trial show primary endpoints met, with non-inferior immune responses observed in adults aged 50-59 compared to adults aged 60 and older.
An RSV vaccine has been approved by the FDA. It’s a huge deal.
WEBMay 4, 2023 · Arexvy, which is made by drug manufacturer GSK, is one of two adult RSV vaccines the FDA reviewed at a March 1 meeting. In trials, the vaccine reduced the risk of lower respiratory tract...
GSK Builds Combo Case for RSV, Shingles Shots With Phase III Data
WEB1 day ago · GSK will use these Phase III data to build a regulatory case for the co-administration of Arexvy with Shingrix, which, if approved, could help the company shore up sales for these products. The company plans to file submissions with the FDA and the European Medicines Agency, according to the announcement. Arexvy is …
FDA approves first RSV vaccine, Arexvy, for adults 60 and ... - ABC7 News
WEBMay 3, 2023 · The FDA approved the first RSV vaccine Wednesday, called Arexvy, which is designed to be given as a single shot to adults 60 and over. After a 60-year scientific quest, the world has its first...
- Some results have been removed
Skip to content